These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30276426)

  • 1. [What is certain in the treatment of rheumatoid arthritis?].
    Witte T
    Internist (Berl); 2018 Dec; 59(12):1249-1254. PubMed ID: 30276426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug therapy of rheumatoid arthritis: where do biologics and novel synthetic disease-modifying antirheumatic drugs stand today?].
    Kaudewitz D; Lorenz HM
    Inn Med (Heidelb); 2023 Oct; 64(10):1005-1012. PubMed ID: 37493758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.
    Kang EH; Liao KP; Kim SC
    Curr Rheumatol Rep; 2018 May; 20(7):42. PubMed ID: 29846814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of rheumatoid arthritis: Unraveling the conundrum.
    Zampeli E; Vlachoyiannopoulos PG; Tzioufas AG
    J Autoimmun; 2015 Dec; 65():1-18. PubMed ID: 26515757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
    Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
    Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase inhibitors for rheumatoid arthritis.
    Yamaoka K
    Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biologics and further new drugs for rheumatic diseases since 2000].
    Krüger K
    Orthopade; 2018 Nov; 47(11):906-911. PubMed ID: 30280235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis.
    Favalli EG; Matucci-Cerinic M; Szekanecz Z
    Autoimmun Rev; 2020 Jan; 19(1):102421. PubMed ID: 31733368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
    Yen JH
    Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
    Tanaka Y; Hirata S
    Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical approach to a patient with rheumatoid arthritis].
    Perković D; Kaliterna DM; Krstulović DM; Bozić I; Borić K; Radić M
    Reumatizam; 2014; 61(2):24-30. PubMed ID: 25427391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current concepts in the management of rheumatoid arthritis.
    Tanaka Y
    Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of rheumatoid arthritis.
    Gaffo A; Saag KG; Curtis JR
    Am J Health Syst Pharm; 2006 Dec; 63(24):2451-65. PubMed ID: 17158693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [JAK inhibitor].
    Yamaoka K; Tanaka Y
    Nihon Rinsho; 2013 Jul; 71(7):1243-7. PubMed ID: 23961674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term impact of delay in assessment of patients with early arthritis.
    van der Linden MP; le Cessie S; Raza K; van der Woude D; Knevel R; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2010 Dec; 62(12):3537-46. PubMed ID: 20722031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutics in rheumatoid arthritis.
    Savage C; St Clair EW
    Rheum Dis Clin North Am; 2006 Feb; 32(1):57-74, viii. PubMed ID: 16504821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.